evrysdi
Pharmaranks rates Evrysdi 3.6/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Evrysdi (Risdiplam) is a medication used to treat Spinal Muscular Atrophy.
Risdiplam · by Genentech Inc
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Risdiplam
- Form
- Powder, Tablet
- Strength
- Risdiplam 5MG
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- spinal muscular atrophy
- Manufacturer
- Genentech Inc
- FDA application
- NDA219285
Storing Evrysdi, and how long it keeps
Quoted from this product’s own FDA label. Storage belongs to the product and its device, not to the drug in general — a pen and a tablet of the same medicine are kept completely differently.
- “Discard any unused portion 64 days after constitution.”
- “Keep the constituted oral solution of EVRYSDI in the original amber bottle to protect from light.”
May treat (source: NIH RxClass)
Dosage forms
Powder and Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Evrysdi treat?
- Evrysdi (Risdiplam) may be used to treat spinal muscular atrophy, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Evrysdi rated?
- pharmaranks gives Evrysdi a composite score of 3.6 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Evrysdi?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Evrysdi. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Evrysdi?
- Evrysdi is marketed by Genentech Inc. You can see Genentech Inc's full profile, rating, and other products on pharmaranks.
- Is Evrysdi a brand-name or generic drug?
- Evrysdi is a brand-name product with the active ingredient Risdiplam.
- Is Evrysdi available over the counter?
- No. Evrysdi is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Evrysdi come in?
- Evrysdi is currently marketed as powder and tablet, per the FDA's National Drug Code Directory.
- Is Evrysdi FDA-registered?
- Evrysdi is on record with the U.S. FDA under application number NDA219285. You can verify this on its official FDA label.
- Has Evrysdi been recalled by the FDA?
- Evrysdi has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Evrysdi safe?
- There's no single safe-or-not verdict. pharmaranks gives Evrysdi a recall-safety score of 72/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about RISDIPLAM
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 618 reports naming RISDIPLAM — the active ingredient in Evrysdi, and the FDA flagged 75% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- pneumonia38 reports
- diarrhoea33 reports
- vomiting30 reports
- pyrexia25 reports
- muscular weakness21 reports
- rash20 reports
- hypokalaemia17 reports
- nausea17 reports
Read these as a signal, not a rate. A report does not mean RISDIPLAM caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
benzamycin
Benzoyl Peroxide and Erythromycin
colazal
Balsalazide Disodium
cuprimine
Penicillamine
mysoline
Primidone
retin-a
Tretinoin
tolak
Fluorouracil
Compare Evrysdi head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
evrysdi
72/100